Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
China
· Delayed Price · Currency is CNY 58.37
-1.35 (-2.26%)
Mar 9, 2026, 3:00 PM CST
SHA:688399 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 340.38 | 331.36 | 380.05 | 4,336 | 2,340 | Upgrade
|
| Other Revenue | - | 18.25 | 23.13 | 1,199 | 499.11 | Upgrade
|
| Revenue | 340.38 | 349.61 | 403.18 | 5,535 | 2,839 | Upgrade
|
| Revenue Growth (YoY) | -2.64% | -13.29% | -92.72% | 94.95% | 63.19% | Upgrade
|
| Cost of Revenue | - | 147.64 | 253.94 | 2,380 | 879.96 | Upgrade
|
| Gross Profit | 340.38 | 201.97 | 149.24 | 3,155 | 1,959 | Upgrade
|
| Selling, General & Admin | - | 214.27 | 377.62 | 720.25 | 534.41 | Upgrade
|
| Research & Development | - | 100.52 | 135.39 | 185.32 | 106.35 | Upgrade
|
| Other Operating Expenses | 371.27 | -7.42 | -8.87 | 17.48 | -5.25 | Upgrade
|
| Operating Expenses | 371.27 | 270.92 | 533.52 | 981.87 | 648.43 | Upgrade
|
| Operating Income | -30.89 | -68.95 | -384.28 | 2,173 | 1,311 | Upgrade
|
| Interest Expense | - | -7.75 | -6.94 | -5.33 | -3.96 | Upgrade
|
| Interest & Investment Income | - | 39.78 | 57.56 | 42.74 | 26.83 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -2.74 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.1 | -1.19 | 0.76 | -1.53 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.72 | -0.49 | -0.16 | -0.33 | -3.33 | Upgrade
|
| EBT Excluding Unusual Items | -31.62 | -36.31 | -335.02 | 2,211 | 1,326 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.83 | 13.12 | 48.15 | 32.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 2.07 | -2.92 | -1.44 | 2.97 | Upgrade
|
| Asset Writedown | - | -9.33 | -79.01 | -140.31 | - | Upgrade
|
| Other Unusual Items | - | 46.93 | 28.16 | 21.76 | 30.72 | Upgrade
|
| Pretax Income | -31.62 | 4.19 | -375.67 | 2,139 | 1,392 | Upgrade
|
| Income Tax Expense | 8.09 | 6.19 | -1.86 | 310.81 | 198.56 | Upgrade
|
| Net Income | -39.71 | -2 | -373.81 | 1,828 | 1,193 | Upgrade
|
| Net Income to Common | -39.71 | -2 | -373.81 | 1,828 | 1,193 | Upgrade
|
| Net Income Growth | - | - | - | 53.19% | 45.59% | Upgrade
|
| Shares Outstanding (Basic) | 84 | 99 | 87 | 87 | 87 | Upgrade
|
| Shares Outstanding (Diluted) | 84 | 99 | 87 | 87 | 87 | Upgrade
|
| Shares Change (YoY) | -14.31% | 13.71% | -0.06% | 0.03% | -0.03% | Upgrade
|
| EPS (Basic) | -0.47 | -0.02 | -4.31 | 21.07 | 13.76 | Upgrade
|
| EPS (Diluted) | -0.47 | -0.02 | -4.31 | 21.07 | 13.76 | Upgrade
|
| EPS Growth | - | - | - | 53.14% | 45.64% | Upgrade
|
| Free Cash Flow | - | 83.06 | -224.48 | 1,614 | 681.91 | Upgrade
|
| Free Cash Flow Per Share | - | 0.84 | -2.59 | 18.60 | 7.86 | Upgrade
|
| Dividend Per Share | - | - | - | - | 6.757 | Upgrade
|
| Dividend Growth | - | - | - | - | 42.86% | Upgrade
|
| Gross Margin | 100.00% | 57.77% | 37.02% | 56.99% | 69.01% | Upgrade
|
| Operating Margin | -9.08% | -19.72% | -95.31% | 39.26% | 46.16% | Upgrade
|
| Profit Margin | -11.67% | -0.57% | -92.72% | 33.03% | 42.03% | Upgrade
|
| Free Cash Flow Margin | - | 23.76% | -55.68% | 29.16% | 24.02% | Upgrade
|
| EBITDA | 18.47 | -19.59 | -315.5 | 2,256 | 1,344 | Upgrade
|
| EBITDA Margin | 5.43% | -5.60% | -78.25% | 40.76% | 47.35% | Upgrade
|
| D&A For EBITDA | 49.36 | 49.36 | 68.78 | 83.4 | 33.63 | Upgrade
|
| EBIT | -30.89 | -68.95 | -384.28 | 2,173 | 1,311 | Upgrade
|
| EBIT Margin | -9.08% | -19.72% | -95.31% | 39.26% | 46.16% | Upgrade
|
| Effective Tax Rate | - | 147.81% | - | 14.53% | 14.27% | Upgrade
|
| Revenue as Reported | - | 349.61 | 403.18 | 5,535 | 2,839 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.